WEBULL
WebtradeDownload

Can Genmab (CPSE:GMAB) Still Be A Bargain On Cash Flow?

Simply Wall St · 2d ago

Genmab has surged to the forefront of biotech conversations after a sharp run in the share price, which raises a straightforward question for you as an investor. Are today’s levels still grounded in the cash flows that the business is expected to generate, or has sentiment run ahead of the underlying economics?

  • Genmab has delivered a 105.9% return over the past year, which puts real pressure on the valuation to be supported by the cash the company can produce over time.
  • Positive Phase 3 results for petosemtamab and rinatabart sesutecan may support higher expectations for future revenue streams and could shift the timing and durability of Genmab’s cash inflows if these programs move toward approval and commercialization.
  • Prefer to judge Genmab on earnings? See why Genmab's 42.9x P/E tells a different valuation story.

The issue now is whether the current share price can be justified by Genmab’s intrinsic value when it is valued through its cash flows using a Discounted Cash Flow (DCF) approach.

If you want to see how other businesses with strong medical or technology themes compare on quality and valuation, it is worth lining Genmab up against 194 high quality undervalued stocks.

Is Genmab Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model used here takes Genmab’s projected cash generation and discounts it back to today. On the latest numbers, the business produced trailing twelve month free cash flow of about US$838 million, and analysts see this stream growing toward multi billion dollar levels over the coming decade, which is consistent with the 2 Stage Free Cash Flow to Equity setup that tapers growth over time.

Based on those assumptions, the DCF outcome suggests an estimated intrinsic value that sits substantially above the current share price of DKK3,788.00. Positive Phase 3 results for petosemtamab in head and neck cancer treatment help explain why the market is starting to price more of Genmab’s future cash flows into the stock. At the same time, the model still indicates potential upside that is based purely on projected free cash generation. Find out what Genmab could be worth using our Discounted Cash Flow (DCF) estimate.

The Genmab Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Genmab pick up where the DCF debate leaves off and explain which paths for Genmab's growth, profitability and earnings would need to occur for the stock to be worth significantly more or less than today’s market price, all hosted on the Community page. Each narrative links its number to a specific view on how revenue momentum, cost structure and risk factors could change, which you can revisit as new information appears.

One of the top community narratives on Genmab: 36% overvalued

"The main thing that has to go right is that Genmab converts its broad Phase 3 pipeline in EPKINLY, Rina S and petosemtamab…"

Discover why this Narrative puts Genmab at 36% overvalued.

Genmab’s value still hinges on one unresolved piece

Price, pipelines and projected cash flows only matter if the people steering Genmab and setting their own pay are aligned with you as a shareholder, which is a separate question altogether. See who runs Genmab and how they are paid.